Long-Term Low-Carb Diet Efficacious for Treating Dyslipidemia in T2D
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 2, 2024 -- For individuals with type 2 diabetes, long-term low-carbohydrate diets (LCD) are efficacious for treatment of dyslipidemia but do not affect glycemic control, according to a review published online July 24 in the Journal of Diabetes Investigation.
Takahiro Ichikawa, from the Kyoto Prefectural University of Medicine in Japan, and colleagues conducted a systematic review to examine the association between long-term LCD and glycemic control in individuals with type 2 diabetes. Six studies met the inclusion criteria.
The researchers found no significant differences in changes in glycated hemoglobin (HbA1c) between long-term LCD and control diets. Furthermore, between long-term and control diets, there were no significant differences in the changes in weight loss, blood pressure, and low-density lipoprotein cholesterol. Compared with control diets, long-term LCD were associated with greater elevation in high-density lipoprotein cholesterol (standardized mean difference, 0.22) and a decrease in triglyceride levels (standardized mean difference, −0.19).
"Long-term LCD might be an important approach in the management of diabetic dyslipidemia in individuals with type 2 diabetes," the authors write. "However, in the present study, long-term LCD were not found to be more effective than control diets in the reduction of HbA1c levels."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...
Increasing Proportion of U.S. Adults Unaware They Have Hypertension
MONDAY, June 9, 2025 -- From 2013 to 2023, there was an increase in the proportion of U.S. adults who were unaware of having hypertension, according to a research letter published...
Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM
MONDAY, June 9, 2025 -- For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.